Physician profile
Benjamin Shekhtman
NPI 1316407448
$1,753.26
in general payments reported to CMS, 2019-2025
10 companies · $835 in 2025
The $835 reported for 2025 was more than what 85% of Physical Medicine & Rehabilitation providers received nationally (typical 2025 total: $138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $32.02 · 2022: $709 · 2023: $178 · 2025: $835.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $538 · Travel and Lodging: $475.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $537.73 |
| Travel and Lodging | $474.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Curonix LLC | $834.62 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Becton, Dickinson and Company | $470.00 | 2022 | |
| Medtronic, INC. | $135.05 | 2022-2023 | Intellis Adaptivestim |
| Avanir Pharmaceuticals, INC. | $109.69 | 2022 | |
| Abbvie INC. | $93.39 | 2023 | Botox |
| Saol Therapeutics INC. | $32.02 | 2021 | |
| Amneal Pharmaceuticals LLC | $22.18 | 2023 | Lioresal (Baclofen) |
| Avanos Medical | $20.75 | 2022 | |
| Si-Bone, INC. | $17.86 | 2023 | |
| Pacira Pharmaceuticals Incorporated | $17.70 | 2023 | Zilretta, Exparel, Iovera |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Shekhtman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.